Lab Product News
News

Collaborative study aims to identify breast cancer mutations


Toronto, ON – The Ontario Institute for Cancer Research (OICR) has entered into a new collaborative research study with Thermo Fisher Scientific and Queen’s University to help bring more targeted diagnosis and treatment to breast cancer patients in the future.

The study, led by Dr. John Bartlett, director of OICR’s Transformative Pathology Program, and Dr. Harriet Feilotter, Department of Pathology and Molecular Medicine, Queen’s University, aims to identify mutations and copy number changes found in breast cancer samples and establish whether these abnormalities correlate with on-market drugs, available clinical trials, or published studies.

OICR-affiliated researchers and collaborators at Queen’s University and Sunnybrook Health Sciences Centre will process the same breast cancer samples to establish whether the results are reproducible at different sites. This study will also characterize more than 400 additional retrospective breast cancer samples supporting ongoing clinical research efforts of Dr. Bartlett’s team at OICR, which strives to improve the clinical management of the disease.

Collaborators Drs. Martin Yaffe and Arun Seth at Sunnybrook Health Sciences Centre will provide laboratory space and additional technical support for the study. Dr. Yaffe is also co-leader of OICR’s Smarter Imaging and Imaging Translation Programs.

The study will use Thermo Fisher’s Oncomine Comprehensive Assay, a targeted, next-generation sequencing (NGS) research tool that analyzes 143 genes relevant to cancer and which is the NGS assay used for the NCI-MATCH study in the United States. The data generated can be further studied with the Oncomine Knowledgebase Reporter, which is a curated set of published evidence that matches driver genetic variants with relevant information, such as on-market drugs, available clinical trials, or published studies. The findings of the OICR study will be used to assess the technology and could inform subsequent clinical trials.

“Our ultimate goal is to one day be able to better stratify breast cancer patients, meaning we will be able to improve our understanding of the unique characteristics driving their cancer and better link patients with drugs or with clinical trials that can help them,” said Bartlett. “If successful this study could lead to more molecular diagnostics and more information for breast cancer patients when they receive their diagnosis.”

“For these types of studies, clinical researchers anticipate receiving numerous samples that may be partially degraded with little viable nucleic acid material,” said Andy Felton, PhD, vice president of product management for clinical next generation sequencing at Thermo Fisher. “The Oncomine Comprehensive assay and Ion Torrent NGS systems yield robust results with challenging samples, essential performance requirements for platforms that will contribute to the advancement of precision medicine.”

Drs. Feilotter and Bartlett have also engaged six laboratories in Ontario, including at Hamilton Health Sciences, London Health Sciences Centre, Ottawa General Hospital, Sunnybrook Health Sciences Centre, Sudbury Health Science North and University Health Network to look at the robustness and reproducibility of the assay across different cancer samples. This collaboration could extend the findings of this study beyond breast cancer to other common cancers.